Clinical Observation On Combined Therapy Of Transcatheter Arterial Chemembolization And Percutaneous Radiofrequency Ablation For Treatment Of Primary Hepatocellular Carcinoma

[Objective] To evaluate the clinical efficacy and adverse reactions of the combined therapy of transcatheter arterial chemoembolization (TACE) and percutaneous radiofrequency ablation (RFA) for primary hepatocellular carcinoma(PHC).[Methods] Sixty-four patients with unresectable hepatocellular carcinomas,were divided into two groups:thirty-five patients received a combined therapy of TACE and RFA, whereas the rest cases underwent TACE alone. TACE was performed firstly for both groups by using iodinated oil5～20ml+MMC4～10mg+CBP25～100mg+E-ADM10～30mg+Gelfoam through Seldinger’s method. The procedure would be repeated3～4weeks later and all patients received it for1to3times generally.After2weeks of interval, patients in the combined therapy group received RFA under the guidance of ultrasonography as planned. The tumors which size were less than3cm were performed at one targeted point only once,while the larger ones were at varies points from different layers for several times. The short-term effects were evaluated in accordance with WHO solid tumor evaluation standard and long-term effects by3-year survival rate. Observe the short-term and long-term effects of the combined therapy as well as adverse reactions with reference to the WHO anticancer corresponding standard. SPSS17.0statistic software was used to analyze the datas.The enumeration datas were estimated by chi-square test, the measurement datas by t-test.survival analysis by the Kaplan-Meier method, and differences between survival curves by the Log-Rank test.lt was provided that the difference had a statistical significance as P<0.05.[Results]①The short-term effect:the response rate (RR) in the combined therapy group and the control group were77.14%and51.72%.respectively,and the difference between them was statistically significant (P<0.05)②Survival analysis: The overall survival rates of1,2and3-year and the median survival time in the combined therapy were79.7%,52.3%,23.0%,25months,whereas those of the control group were59.4%,20.3%,6.8%,15months,respectively.The datas above had a significantly statistical difference (P<0.05).③Adverse reactions:the difference between the two groups was not statistically significant (P>0.05).[Conclusions] The combined therapy of TACE and RFA in our study showed satisfactory effecacy in suppressing the growth of tumors and prolonging the patients’survival period with little tolerable side-effects.